genetically engineered hematopoietic stem cells

Cell therapyexperimental

Clinical trial activity

2 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Feb 22, 2012 (NCT01331018)

Timeline

2010s

  1. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Stem CellSupplementation

    Stem Cell supplementation

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • genetically engineered hematopoietic stem cells
  • genetically engineered hematopoietic stem/progenitor cells

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03157804Phase 1/Phase 2 (Phase 2)Jan 1, 2016CIEMAT, Hospital Infantil Universitario Niño Jesús, Madrid, Spain, Universidad Autonoma de Barcelona, Universidad Autonoma de Madrid
NCT01331018Phase 1Feb 22, 2012National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), Rocket Pharma Limited, University of Washington
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
CIEMATAcademic/Hospital1012016
Hospital Infantil Universitario Niño Jesús, Madrid, SpainAcademic/Hospital1112016
National Cancer Institute (NCI)Government1012012
National Heart, Lung, and Blood Institute (NHLBI)Government1012012
Rocket Pharma LimitedFor profit1012012
Universidad Autonoma de BarcelonaAcademic/Hospital1012016
Universidad Autonoma de MadridAcademic/Hospital1012016
University of WashingtonAcademic/Hospital1112012
8 organizations
Page 1 / 1